Covid Research

A note about the COVID-19 pandemic:

CMM is adhering to all University of Arizona guidelines regarding COVID-19. You can learn more about the university's response to this crisis on the UArizona Coronavirus Information Website

We continue to support the education and training of current and prospective students by offering a large and growing list of online course options, including classes that have been traditionally offered only in person. 



The Vercelli lab is studying the impact of asthma-inducing type-2 cytokines (primarily IL-13 ) and asthma-protective bacterial lysates on the expression of ACE2, the SARS-CoV-2 spike protein receptor on human airway epithelial cells.





The Churko lab is exploring the impact that SARS-CoV-2 plays on the heart. Specifically, their lab is exploring drugs that can block and facilitate SARS-CoV-2 entry into the heart.





The Cusanovich lab has been evaluating novel SARS-CoV-2 viral testing technologies that are cheaper, more scalable, and less resource-intensive than traditional assays. The group evaluated a sequencing-based assay called "Swab-Seq” and adapted it for use with less invasive saline gargle samples.




The Ledford lab has been working on a cross-departmental collaboration. A collaboration between the Drs. Ledford (CMM), Vercelli (CMM) and Kraft (DOM) shows that Surfactant Protein-A (SP-A) interacts with SARS-CoV-2. Early studies have shown that SP-A can bind to ACE2, the main receptor for SARS-CoV-2, which may prevent viral entry into respiratory cells and COVID infection.